Strategic partnerships Molteni Farmaceutici has ongoing and recent high-profile collaborations with OncoZenge, Tilray and academic/government institutions, indicating a proactive openness to co-development, licensing and distribution partnerships that can be leveraged to expand Europe-focused cannabis-derived therapies and controlled-substance offerings.

Pain and addiction focus The company specializes in pain management, substance use disorder treatment, and supportive care, creating opportunities to cross-sell novel formulations, extended-release products, and combination therapies to healthcare systems seeking comprehensive pain and addiction management solutions.

European manufacturing hub With an advanced integrated development and manufacturing facility near Florence and a history of handling controlled substances, Molteni is well-positioned to scale EU GMP compliant production for complex therapies, enabling co-licensing or contract manufacturing for partners expanding in Europe.

Global market expansion An expanding international presence, long-standing global partnerships, and emphasis on Made in Italy can be leveraged to pursue international distribution deals, regulatory support, and market-entry partnerships in regions prioritizing Italian-origin pharmaceutical excellence.

Financial leverage With revenue in the tens of millions and a focused product portfolio, there is room to propose value-add deals such as exclusive distribution, joint ventures, or technology transfers for higher-margin therapies, especially in controlled substances and cannabis-derived products.